reduces kynurenine levels and alleviates obesity and related metabolic disorders in model mice.

Source: PubMed, NCBI / U.S. National Library of Medicine

Next-generation probiotics derived from gut commensals show promise for metabolic disease intervention, yet effective anti-obesity strains remain limited. Here, we demonstrate that oral administration ofmarkedly alleviates obesity and metabolic dysfunction in high-fat diet-induced obese mice. Treatment reduced food intake, improved glucose tolerance and insulin sensitivity, lowered blood glucose and lipid levels, and attenuated hepatic steatosis and adipose accumulation.increased the levels of plasma GLP-1 and ileal GLP-1 receptor expression while decreasing ghrelin level, suggesting modulation of gut hormone regulation.also suppressed systemic and colonic inflammation, accompanied by upregulation of metabolic homeostasis-related genes (,,). Targeted and quantitative metabolomics identified altered gut metabolic profiles, particularly reduced kynurenine levels.assays further showed thatconverted kynurenine into kynurenic acid, and its lysate reversed kynurenine-induced lipid accumulation, inflammation, and PPARγ suppression in hepatocytes, providing mechanistic support for the observedmetabolic benefits. These findings supportas a promising next-generation probiotic for obesity management.